You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Pharma Equity Group - Market Update & Q&A
Meet and ask questions to CEO Thomas K. Selsø from Pharma Equity Group on Monday, December 11th, 2023 at 2 PM. CEO Thomas K. Selsø will provide an update on what has happened in 2023 and outline focus areas for 2024 which will be followed by a Q&A session. No question is too big or too small, everyone should have the opportunity to ask questions.
Pharma Equity Group focuses on repositioning existing APIs (Active Pharmaceutical Ingredients) for other indications. Pharma Equity Group acquired a larger portfolio of phase 2 projects through the purchase of Reponex, within major disease areas. These include bacterial peritonitis, chronic skin wounds, inflammatory bowel diseases, as well as colon and rectal cancer. The company operates with a partnership structure for all its phase 3 projects.
Disclaimer: HC Andersen Capital receives payment from Pharma Equity Group for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 20.11.2023, 2.45 PM.